The comments on the previous web-pages strongly suggest that dietary insufficiency may contribution to the development of the symptomatology associated with Dementia and Alzheimer's disease. To date there have been no definitive trials that have shown that nutrient supplementation can halt or reverse the development of Alzheimer's disease, however, none of the previous trials have addressed the causes as outlined previously. It is hoped that this page can provide a number of potential areas of nutritional supplementation that may be beneficial in the prevention of AD, and possibly halt or reverse early signs of dementia.
Lowering Homocysteine: Clearly lowering homocysteine is desirable. This can be achieved through dietary intake of sufficient folate, vitamin B6, iron, vitamin B2 and vitamin B12. In individuals with suspected hypothyroidism this should be treated/corrected and dietary iodine, selenium and molybdenum included or supplemented. With vitamin B12 this is a little bit more difficult as once a person becomes deficient, it is very hard to achieve sufficiency through diet. Further, many people do not gain benefit even from injection of the provitamins cyanocobalamin or hydroxocobalamin and so mixed adenosyl/methyl cobalamin supplementation would be desirable. There have been many oral supplementation trials examining the effect of high dose cyanocobalamin and folate +/- other B group vitamins on lowering homocysteine and attempting to increase the Mini-Mental State Examination (MMSE) scores (reviewed in (1)). Whilst some of the trials were successful in lowering homocysteine no trial using oral supplementation achieved an increase in MMSE. Despite this the trials have been repeated over and over again, and in an almost "Ground hog" like fashion have repeatedly administered oral high dose cyanocobalamin and folate +/+ other B groups, and expected or hoped for a different result. This result would be totally expected as delivery of vitamin B12 to the brain is exceedingly difficult and the amount of vitamin B12 taken up from the gut is very low. In line with what is known about the blood-brain barrier, even the smallest of water soluble molecules is actively excluded from entering the brain. Further, even with the injection of radiolabeled vitamin B12 derivatives less than 0.01% of the dose reaches the brain. No wonder then that the very limited uptake that is achievable from oral delivery of vitamin B12 would be totally ineffectual in "loading" up the brain.
Vitamin B12: Vitamin B12 plays a critical role in myelination, both in the provision of the methyl group for methylation of myelin basic protein and also in the correct processing of methyl malonic acid. Vitamin B12 lack has been associated with incorporation of faulty lipids into the myelin sheath and in the production of faulty myelin basic protein, and destruction of the myelin sheath is a feature of vitamin B12 deficiency. Demyelination is a feature of Alzheimer's disease, and loss of myelinated axons has been found in AD(2). Vitamin B12 deficiency is correlated negatively with cognitive functioning, and is associated with memory impairment, slowness of thought, attention deficits and dementia (3,4,5). It is also associated with decreased nerve conduction velocity (6).Whilst overt B12 deficiency is easily defined levels of B12 even as high as 350 pmol/L have been associated with brain shrinkage, which has also been shown to be associated with cognitive decline (7,8). It would therefore appear logical to maintain vitamin B12 levels that are considerably higher than this. The close relationship between folate and vitamin B2 with maintaining methyl B12 levels, would intimate that it is also essential to maintain adequate levels of these two vitamins as well. In this regard, it has been shown that supplementation with folic acid, vitamin B6 and vitamin B12 was able to slow brain shrinkage in elderly subjects with increased dementia risk (8,9,10,11,12). Unfortunately they did not go further and also supplement with vitamin B2. Vitamin B12 supplementation is also warranted due to the role of Methyl B12 in the formation of choline and the findings of greatly reduced levels of B12 in the brains of elderly persons (13). Vitamin B12 intake should equal or exceed 6 ug/day in persons who do not have other undelying complications, such as sub-optimally treated hypothyroidism, use of PPIs, GORD medication, pernicious anaemia, use of MetforminTM medication, the presence of atrophic gastritis, or other B12 modifying conditions. In these cases higher supplementation should be attempted either by injection or by other high supplementation methods, such as transdermal application.
It should be noted, that successful cycling of vitamin B12, particularly methyl B12 requires functional vitamin B2, which in turn requires adequate intake of Iodine (150-300 ug/day), selenium (55-200 ug/day) and molybdenum (100-200 ug/day). I/Se/Mo are not normally incorporated in most multi-vitamin formulations, although this is changing.
Rate of brain atrophy has been slowed by ultra-high dose administration of a mixture of L-methylfolate, methylcoblamin, and N-acetyl cysteine (14).
Successful reversal of fronto-temporal dementia has been reported in an elderly gentleman who was given repeated injections of high dose vitamin B12 (15). Whilst broad neurological disorders, including poor Hasegawa dementia scale ratings were greatly improved by supplementation with high dose injected methylcobalamin (16). Similarly improvement in cognitive function was also achieved by intravenous methylcobalamin (17).
MethylB12 due to its role in recycling homocysteine, methionine and eventually S-Adenosylmethionine, also has a critical role in the production of creatine, and creatine-phosphate, and also in the production of ubiquinone. Lack of production of creatine, and/or ubiquinone have both been correlated with lower cognitive function and intellectual disability. Serum coenzyme Q10 have been found to be inversely associated with the risk of disabling dementia. For some reason, methyl-B12's critical role in the production of these very important energy related molecules has been missed by all but a few who work in the field.
Iron: Supplementation with heme iron or addition of iron containing foods may be of benefit. Measurement of iron deficiency as per levels of serum ferritin is highly controversial, but it is generally agreed that iron deficiency anaemia occurs at around 20 ug/L ferritin, mild iron deficiency initiating symptoms such as restless leg syndrome occurring at round 50 ug/L with some evidence of iron deficiency occurring between 50-100 ug/L. Evidence of reduced mitochondrial energy output is definitely apparent at levels below 70 ug/L ferritin. Data looking at ferritin levels, in individuals where one would assume maximum benefit from iron would be desirable, have shown that the highest performing athletes had levels of between 80-185 ug/L (mean 134 ug/L)(2). Iron intake should equal or exceed 9 mg/day for men and post-menopausal women. Studies looking at chronic heart failure suggest that levels below 100 ug/L ferritin are of potential risk. It is apparent that as iron levels decrease, iron is lost from muscles, brain and heart, and lack of iron in muscles can account for the frailty, which is characteristic of dementia.
Aconitase: Aconitase is arguably one of the most important enzymes in the citric acid cycle, and reduced activity of the enzyme, due to lack of formation of iron-sulphur complexes will lead to a greatly decreased energy output by the mitochondria. Enzymatic activity has been shown to be reduced in conditions of sub-optimal iron concentrations and sub-optimal sulphur concentrations. Increasing levels of iron/ferritin and conditions that increase the processing of sulphur from dietary methionine, should favour increased aconitase activity. The inflection point for loss of aconitase activity is around 70 ug/L ferritin, which is considerably higher than many pathology laboratories would "flag" as deficiency. Thus, potentially many individuals with sub-optimal iron levels are not being treated for non-anaemic iron deficiency. Thus, maintenance of sufficient iron in the diet, plus intake of sulphur in the form of methionine, and ensuring sufficient vitamin B2 and vitamin B6 would all help to provide sufficient iron and sulphur to maintain the activity of aconitase. In addition it has been shown that elevated production of S-Adenosylmethionine (SAM) is required in order to move sulphur from the methylation cycle to the sulphation cycle for incorporation into Fe-S proteins. This further predicates the maintenance of high levels of active vitamin B12, sufficient folate and active vitamin B2.
Hydrogen sulfide: Given that generation of H2S occurs as a result of processing of homocysteine by the enzyme cystathionine beta synthase, conditions that increase the processing of homocysteine by CBS will also increase the production of CBS, viz: increased iron, B6 and B2, and increased dietary methionine, elevated vitamin B12, and sufficient folate.
Acetylcholine: Studies examining plasma phosphatidylcholine docosahexaenic acid (DHA) showed that those who had a higher mean intake of DHA had a significant (47%) reduction in the risk of developing all-cause dementia (18). This is in contrast to studies in which lecithin supplementation did not affect the risk of development of dementia (19). Dietary supplementation with egg yolk phosphatidylcholine has shown memory improvement in models of AD (20). Once again supplementing with methyl B12, folate and vitamin B2 should increase methylation and formation of choline and acetylcholine, which should help to reduce the rate of degeneration of cholinergic neurons, which is a feature of AD (21,22,23).
Increased blood supply to the brain: The mantra for preventing AD has for a long time been "diet and exercise", however, the benefits of this are generally not explained. Evidence suggests that there is restricted blood supply to the brains in AD, and the thought is that increasing the exercise regime will increase the blood supply to the brain. There is potentially a nutritional way to increase blood supply to the brain and that is by providing iron, FMN/FAD and BH4 for increasing the activity of the enzyme, NOS. Increased generation of the vasodilator nitric oxide by eNOS, has been shown to increase cognitive function (24). Aberrant NOS activity is a feature of AD (25). Reduced NOS activity has also been shown to increase the formation of amyloid precursor protein (26). Boyle and co-workers (27) found a correlation between lack of physical activity, increased weight and brain atrophy in AD. Somewhat at odds with this finding was the lack of correlation between elevated systolic blood pressure and dementia in those above 80 (28).
Summary: Looking at the above solutions it is apparent that if there single nutrient deficiency, specifically active vitamin B2, the activity of the other nutrients, vitamin B12, iron, folate and vitamin B6 will be compromised. This is very similar to the nutrient suggestions suggested by the works of Douaud (9) and de Jager (10), who have demonstrated the effectiveness of folate, vitamin B12 and vitamin B6, with the addition of heme iron and vitamin B2. Curiously, lack of the single nutrients selenium (55 ug/day) or molybdenum (100 ug/day) or iodine (150 ug/day), could have similar effects due to their importance in the generation of active B2 (FAD). Similarly, lack of vitamin B12 (6 ug/day), due to it's role in folate processing, reducing homocysteine, stimulation of SAM, with resultant movement of sulphur from methionine into the synthesis of iron-sulphur porteins, and the resultant increase in energy production by the citric acid cycle through aconitase activity. Apart from the nutrient suggestions, it is generally accepted that obesity and lack of exercise both are associated with a higher incidence of AD. Hence it would appear that a diet that is nutrient rich and calorie sufficient, when combined with moderate amounts of cardiovascular exercise, may be of considerable benefit to those wanting to prevent, halt or even reverse the "dementia" process.
The probability that one can reverse the symptoms of dementia and thereby prevent the onset of Alzheimer's Disease would depend upon finding a way to detect early symptoms of the disease. Given that Alzheimer's Disease is regarded as a classical mitochondrial disease, then assays that can determine the functional activity of the mitochondria should be beneficial.
Potential assays include
(i) direct measurement of aconitase function
(ii) measurement of organic acids in urine, or metabolic analysis.
Currently Great Plains laboratory performs an Organic Acids Test (http://www.greatplainslaboratory.com/organic-acids-test/ ), whilst a similar metabolic test is also carried out by Genova (https://www.gdx.net/product/metabolic-analysis-test-organic-acids-urine ). Both of these tests are capable of identifying metabolic deficiencies that could ultimately lead to dementia/AD.
(iii) measurement of iron status. Steady decline in serum ferritin levels would be indicative of potential problems and could be addressed relatively easily. Experience has show that once serum ferritin levels drop below 70 ug/L, energy production from aconitase starts to drop. This level of ferritin will not however be "flagged" by pathology laboratories whose sole measurement relates to iron deficiency anaemia, rather than to impending energy loss and functional loss of actonitase and succinate dehydrogenase activity.
(iv) falling serum vitamin B12. Falling functional vitamin B12 can be monitored by measuring an increase in the metabolic products MMA and homocysteine. The so-called "active B12 assay" is a complete misnomer, however falls in serum B12 and/or active B12 are representative of loss of total vitamin B12 in serum. Loss of functional vitamin B12 in the brain precedes loss in serum.
(v) reduced production of ubiquinone. Falling functional vitamin B12 can be monitored by measuring reduced production of ubiquinone and hence reduced energy output in the electron transport chain.
It is known that there are at least seven modifiable facts that increase the risk of dementia.
These include, smoking, obesity, high blood pressure (hypertension), inactivity, diabetes, depression and poor education.
Regular exercise that raises the heart rate can increase the flow of blood to the brain, and so reduce the risk of dementia. The exercise has to be intense and increase cardiovascular fitness, as well as increasing the both the muscle mass and muscle strength (29). Additional benefit has been achieved with resistance training (30). Furthermore, regular exercise can also help to reduce the risk of developing dementia as it can help to reduce weight, decrease blood pressure and decrease the risk of diabetes.
Being socially engaged, and participating in activities that stimulate the brain, such as mental challenges and learning new skills, languages, or advanced learning are all associated with a lowered incidence of dementia.
Protect your brain from damage. There are many instances where AD has arisen soon after a mild or severe injury to the brain.
Avoid medications that can affect the uptake and processing of nutrients, including antacids (Prilosec, Nexium, Zantac, Prevacid, Ranitidine, Famotidine, Nazitidine, Cimetidine, etc), and MetforminTM. Avoid bariatric surgery, including bowel resection or gastric by-pass surgery, as well as gastrectromy, particularly of the cardiac or fundus.
Avoid the use of statins. Statins block the enzyme HMG-CoA-reductase, and in so doing reduce the production of precursors involved in the production of ubiquinone, and increase the potential energy output in the electron transport chain and also increase the risk of cardiovascular disorder, depression and heart failure (31)
Further information on preventing and early detection of diabetes can be found on many sites, of which the following is but one (PreventingType2diabetes).
Brain Training and Alzheimer's Disease Prevention
There are several indications that exercising the brain can delay the onset of AD, and George Mears from the Brain Wellness Institute (see email@example.com) has kindly submitted a summary of the latest suggestions for preventing dementia. These suggestions can be found in the attached document. The mechanism whereby the "Brain Training" may have some effect may be as a result of the dopamine reward from successful training experiences. It is known that there is an age related loss of dopaminergic cell bodies in the brain (32), and at least one study has shown that brain training is associated with changes in the density of cortical dopamine D1 receptors (33).
Diet and Alzheimer's Disease Prevention
It is often said that a diet that is good for the heart is good for the brain, and that the best example of such a diet is the Mediterranean diet. More careful analysis reveals that the diet is one of high nutrient density.
Whole grains, brown rice and whole wheat pasta - providing vitamin B1, molybdenum and iodine
Nuts, seeds and beans - providing selenium, molybdenum, manganese and folate
Fresh fruit and vegetables - providing folate and magnesium
Fish, poultry, eggs, some red meat, clams, oysters, and mussels - providing zinc, iodine, biotin, iron and vitamin B12
Milk, cheese, and yoghurt - providing calcium, vitamin B2 and vitamin D.
Diets containing sufficient amounts of vitamin B1 and vitamin B2 can also reduce the risk of diabetes (a preventable risk factor for dementia), due to better blood glucose control.
Clarke etal, 2014 Effects of homocysteine lowering with B vitamins on cognitive ageing: meta-analysis of 11 trials with cognitive data on 22,000 individuals. PMID: 24965307
Habte etal, 2015 Iron, folate and vitamin B12 status of Ethiopian professional runners. PMID: 26719754
Scheltens etal, 1995 Histopathologic correlates of white matter changes on MRI in Alzheimer's disease and normal aging. PMID 7746401.
Wynn and Wynn, 1998 The danger of B12 deficiency in the elderly. PMID 9836201
Bottiglieri 1996 Folate, vitamin B12, and neuropsychiatric disorders.PMID 9155210
Briani etal, 2013 Cobalamin deficiency: clinical picture and radiological findings.PDF
Misra etal, 2003 Vitamin B12 deficiency neurological syndromes: a clinical, MRI and electrodiagnostic study. PMID 12613142
De Jager, 2014 Critical levels of brain atrophy associated with homocysteine and cognitive decline. PMID 24927906
Douaud etal 2013 Preventing Alzheimer's disease-related gray matter atrophy by B-vitamin treatment. PMID 23690582
Durga etal, 2007 Effect of 3-year folic acid supplementation on cognitive function in older adults in the FACIT trial:... PMID 17240287
de Jager etal, 2012 Cognitive and clinical outcomes of homocysteine-lowering B-vitamin treatment in mild cognitive impairment: A randomized controlled trial. PMID 21780182
Smith etal, 2010 Homocysteine-lowering by B vitamins slows the rate of accelerated brain atrophy in mild cognitive impairment: A randomized controlled trial. PMID 20838622
Zhang etal, 2016 Decreased levels of vitamin B12 in aging, autism and schizophrenia. PMID 26799654
Shankle etal, 2016 CerefolinNAC therapy of hyperhomocysteinemia delays cortical and white matter atrophy in Alzheimer's disease and cerebrovascular disease PMID 27567825
Blundo etal, 2011. Vitamin B12 deficiency associated with symptoms of frontotemporal dementia. PMID 20927562
Katuoka etal, 1997 A case of vitamin B12 deficiency with broad neurological disorders and canities. PMID 9125735
Ikeda etal, 1992 Treatment of Alzheimer-type dementia with intravenous mecobalamin. PMID 1638504
Schaefer et al 2006 Plasma phosphatidylcholine docosahexaemoic acid content and risk of dementia and Alzheimer disease: the Framingham heart study. PMID 17101822
Higgins and Flicker, 2003 Lecithin for dementia and cognitive impairment. PMID 12917896
Moriyama etal, 1996 Effects of dietary phosphatidylcholine on memory in memory deficient mice with low brain acetylcholine. PMID: 8569416
Jiang etal, 2016 Partial BACE1 reduction in a Down syndrome mouse model blocks Alzhemier-related endosomal anomalies and cholinergic neurodegeneration: role of APP-CTF. PMID: 26923405
Lombardo and Maskos, 2015 Role of nicotinic acetylcholine receptor in Alzheimer's disease pathology and treatment. PMID 25514383
Groth etal, 2014 Atrophy of the cholinergic basal forebrain in dementia with Lewy bodies and Alzheimer's disease dementia. PMID 25059393
Lin etal, 2013 Chronic rapamycin restores brain vascular integrity and function through NO synthase activation and improves memory in symptomatic mice modeling Alzheimer's disease. PMID 23801246
de la Monte etal, 2000 Role of aberrant nitric oxide synthase-3 expression in cerebrovascular degeneration and vascular-mediated injury in Alzheimer's disease. PMID: 10818490
Austin etal, 2010 Endothelial nitric oxide modulates expression and processing of amyloid precursor protein. PMID 21127294
Boyle etal, 2015 Physical activity, body mass index, and brain atrophy in Alzheimer's Disease. PMID: 25248607
Ryuno etal, 2016 Differences in the association between high blood pressure and cognitive functioning..... PMID: 27009579
Smith etal, 2010 Aerobic exercise and neurocognitive performance: a meta-analytic review of randomized controlled trials .... PMID: 20223924
Bossers eatl, 2015 A 9-week aerobic and strength training program improves cognitive and motor function in patients with dementia. PMID: 25648055
Maes etal, 2009 Lower plasma Coenzyme Q10 in depression: a marker for treatment resistance and chronic fatigue in depression... PMID: 20010493
Palmer and DeKosky, 1993. Monoamine neurones in aging and Alzheimer's disease. PMID: 19197069
McNab etal, 2009 Changes in cortical dopamine D1 receptor binding associated with cognitive training.. PMID: 19197069
Copyright © 2016 preventingdementia.org. All Rights Reserved.
The statements on this site compose a compendium of generally recognized signs of Alzheimer's disease. They also are formulated from a summary of relevant scientific publications. In addition they may contain some forward looking statements of a general nature.
Reproduction in whole or in part in any form or medium without express written permission is prohibited